The case in front of me: a 30G needle · 3.33 mg/mL.
I want the working, not the result — I need to be able to redo it with different numbers.
I care about the precision as well as the value — I want to know how many figures are real.
Is my approach right even if my number is wrong?
At 3.33 mg/mL every microlitre left behind is 3.33 µg, so a 50 µL hub costs 0.167 mg per draw and a 5 µL fixed-needle barrel costs 0.0167 mg. Multiply by the draws, not by the doses: ten draws through a 50 µL dead space is 1.67 mg gone, which at 3.33 mg/mL is 0.5 mL of solution you paid for and never administered. Against a 2 mg dose that 50 µL is 8.3 per cent; against a 0.25 mg dose it is 66.6 per cent, which is why the loss matters most at exactly the doses where you can least afford it. a 30G needle has a bore, a hub and a length, and the hub dominates: a fixed-needle insulin barrel has almost none, a luer connection has a measurable one before the needle even starts.
Changing syringe architecture changes everything, while changing needle gauge changes almost nothing.
Configuration B — 0.5 mL fixed-needle U-100 insulin syringe, dead space 2 µL: volume removed per draw = 100 + 2 = 102 µL.
| Appearance | Interpretation | Action |
|---|---|---|
| Intact opaque puck, proud of base | Cycle ran correctly | Proceed |
| Slumped to one side | Shipped before fully dry, or vibration | Usually usable; note it |
| Glassy translucent film | Collapse above glass transition | Test before use |
| Melt-back ring at stopper | Thermal excursion in transit | Test before use |
| No visible cake at all | Very low fill, or nothing there | Weigh it; query the supplier |
It helps to be literal here: configuration A — 1 mL luer-lock plus detachable needle, dead space 84 µL: each draw removes 100 + 84 = 184 µL. Draws available from 2,000 µL = 2000 / 184 = 10.87, so 10 full draws.
The World Health Organisation guidance on injection equipment adopted the same high-versus-low dead-space distinction, using a low-dead-space threshold in the low single-digit microlitres.
Worth noting: draw size matters enormously — the smaller your draws, the more the syringe architecture matters.
The switch nearly doubles your vial, which is better than most other optimisations combined.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsStart from the worked arithmetic: a 10 mg vial reconstituted with 2 mL gives 5 mg/mL. One hundred microliter draws are 0.5 mg each. At 84 µL dead space per draw, half your vial disappears into the hub.
Delivered peptide = 10 x 0.5 mg = 5.0 mg. Lost to dead space = 10 x 84 µL = 840 µL x 0.005 = 4.2 mg. Yield = 50 per cent.
Corollary that follows immediately: changing needle gauge or length barely changes your losses.
The limitation is that even with perfect technique, some loss is irreducible unless you switch to a low-dead-space syringe.
If cost matters, this is the first thing to change, not the last.
Dead space is the volume trapped in the syringe hub and needle after the plunger bottoms out, and it is the reason your 10 mg vial yields only 9.5 mg of usable draws.
Low-dead-space syringe designs either have the needle bonded directly to the barrel — a fixed-needle syringe, which is the cheapest route — or add a moulded projection on the plunger tip that fills the luer cone.
Mechanically, the luer cone of the syringe plus the needle's own plastic hub accounts for the vast majority of the dead space.
Published inter-laboratory comparisons of dead-space measurements on identical syringes show good agreement, suggesting the numbers are reliable.
One qualification: the dead space does not affect the dose accuracy if the hub was full of solution at the start of the draw.
Buy the right syringe — a fixed-needle insulin syringe is cheap and solves the problem.
Specifically, a fixed-needle insulin syringe holds roughly 3 to 5 µL dead space and costs the same as a luer-lock syringe with 35 to 100 µL dead space.
The needle lumen volume is under a microlitre in a typical fine-gauge configuration, so the needle is not the problem.
The caveat is that dead space is a yield loss and not a dose-accuracy loss, so the person feeling this loss most is the person with the most total draws.
Write the arithmetic on the vial label. It costs nothing and it removes the step where you reconstruct it from memory at an inconvenient moment.
edited 29 Oct 2024 by v_ramaswamy — clarified the distinction between purity and content
On the detail: dead space is irreducible with a high-dead-space syringe, which is why the hardware matters more than any technique.
The complete rule: fix the syringe architecture first, and then the reconstitution volume becomes a free choice you can make on stability grounds rather than on economics.
Syringe residual volume has been measured properly, mainly in the infection-control literature, with a median residual of about 84 µL for a conventional 1 mL syringe with a detachable needle and roughly 2 µL for a fixed-needle low-dead-space design.
The practical summary: fine gauge, gentle swirl, diluent down the wall, room temperature before drawing, and check the syringe scale against the barrel rather than against your assumption.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.